- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02309255
The NOR-COR Study for Coronary Prevention
The NOR-COR (NORwegian CORonary) Study: Identification of CHD Patients With Poor Adherence to Secondary Prevention and Their Perceived Needs for Follow-up
The NOR-COR study is a cross-sectional, observational study designed to explore a large number of cardiovascular, inflammatory, genetic, behavioral, and psychosocial factors (including anxiety, depression, quality of life) in 1369 patients with established coronary heart disease (CHD) hospitalized in the Sections for Cardiology at the hospitals in Drammen (n=722) and Vestfold (n=647). Study data from an extensive questionnaire, clinical and laboratory data, and sputum/saliva for genetic analyses will be collected.
The main overall aim of the NOR-COR study is to develop new strategies to improve secondary prevention for underserved high risk patient-groups with CHD. The first study phase aims to collect information necessary to develop empirically based future secondary coronary prevention interventions. In a genetic sub-project markers associated with CHD and personality type will be explored.
The study will evaluate current secondary preventive programs and explore the mechanisms that link behavioral, psychosocial, inflammatory, and genetic factors to poor prognosis. The study will in short term provide new knowledge potentially useful for increasing participation in current cardiac rehabilitation/secondary preventive programs. For a longer perspective these associations may be useful for design of new intervention programs to selected high risk patient groups whom may be in need of programs with different content and/or of longer duration than those currently being applied.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
Buskerud and Vestfold
-
Drammen and Tønsberg, Buskerud and Vestfold, Norvège, N-3004
- Vestre Viken HF, Drammen Hospital and The Hospital of Vestfold
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion criteria:
All patients aged 18-80 years with first or recurrent diagnosis or treatments for CHD: a) acute myocardial infarction [ICD-10; I21], b) coronary artery by-pass graft operation (CABG), or c) elective or emergency PCI [ICD-10; I25]) have been identified from hospital patient discharge lists (diagnostic lists) by searching chronologically after last admission the past three years. In patients with recurrent diagnosis the last event will define the event.
Exclusion Criteria:
- Cognitive impairment that would invalidate assessment including all patients living at nursing home and psychosis.
- Short life expectancy (i.e. <1 year) due to terminal heart (NYHA class 4), lung (chronic obstructive pulmonary disease GOLD 4)-, liver- or kidney disease (chronic kidney disease stage 5), malignant disease, or other reason.
- Not able to understand and write the Norwegian language or refuse to give written informed consent to study participation.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
---|---|
coronary heart disease patients
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
Cardiovascular risk factors, lifestyle, and drug adherence
Délai: Within 2 years after study inclusion
|
Within 2 years after study inclusion
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
---|---|
Readmission with a coronary event, acute myocardial infarctrion and cardiovascular mortality
Délai: Within 5 years after study inclusion
|
Within 5 years after study inclusion
|
Autres mesures de résultats
Mesure des résultats |
Délai |
---|---|
The hospital anxiety and depression scale (HADS)
Délai: Within 2 years after study inclusion
|
Within 2 years after study inclusion
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Publications générales
- Sverre E, Peersen K, Perk J, Husebye E, Gullestad L, Dammen T, Otterstad JE, Munkhaugen J. Challenges in coronary heart disease prevention - experiences from a long-term follow-up study in Norway. Scand Cardiovasc J. 2021 Apr;55(2):73-81. doi: 10.1080/14017431.2020.1852308. Epub 2020 Dec 4.
- Sverre E, Peersen K, Weedon-Fekjaer H, Perk J, Gjertsen E, Husebye E, Gullestad L, Dammen T, Otterstad JE, Munkhaugen J. Preventable clinical and psychosocial factors predicted two out of three recurrent cardiovascular events in a coronary population. BMC Cardiovasc Disord. 2020 Feb 5;20(1):61. doi: 10.1186/s12872-020-01368-6.
- Munkhaugen J, Hjelmesaeth J, Otterstad JE, Helseth R, Sollid ST, Gjertsen E, Gullestad L, Perk J, Moum T, Husebye E, Dammen T. Managing patients with prediabetes and type 2 diabetes after coronary events: individual tailoring needed - a cross-sectional study. BMC Cardiovasc Disord. 2018 Aug 3;18(1):160. doi: 10.1186/s12872-018-0896-z.
- Sverre E, Otterstad JE, Gjertsen E, Gullestad L, Husebye E, Dammen T, Moum T, Munkhaugen J. Medical and sociodemographic factors predict persistent smoking after coronary events. BMC Cardiovasc Disord. 2017 Sep 6;17(1):241. doi: 10.1186/s12872-017-0676-1.
- Sverre E, Peersen K, Husebye E, Gjertsen E, Gullestad L, Moum T, Otterstad JE, Dammen T, Munkhaugen J. Unfavourable risk factor control after coronary events in routine clinical practice. BMC Cardiovasc Disord. 2017 Jan 21;17(1):40. doi: 10.1186/s12872-016-0387-z.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- NOR-COR REK ID 2013/1885
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Secondary Coronary Prevention
-
Wafaa Uthman AhmedAin Shams Maternity HospitalInconnueCARBETOCINE POUR LA PREVENTION DE LA RETENUE PLACENTAIREEgypte
-
Bambino Gesù Hospital and Research InstituteComplétéObésité pédiatrique sévère (IMC > 97° pc -Selon les Centers for Disease Control and Prevention BMI Charts-) | Tests de la fonction hépatique altérée | Intolérance glycémiqueItalie
Essais cliniques sur aucune intervention
-
Otsuka Pharmaceutical Factory, Inc.CelerionComplété
-
University of MinnesotaComplété
-
Assistance Publique - Hôpitaux de ParisComplété
-
Milton S. Hershey Medical CenterPas encore de recrutementMaladies du foie | NASH - Stéatohépatite non alcoolique | NASH
-
University of CologneComplétéAccident vasculaire cérébral | ApraxieAllemagne
-
Northwestern UniversityComplétéLa dépression | AnxiétéÉtats-Unis
-
H2O Health and Agriculture LLCInconnuePneumonie | DiarrhéeGuatemala
-
Eunah Cho, MDComplétéRécupération postopératoireCorée, République de
-
University of California, Los AngelesInconnue
-
Johns Hopkins UniversityAstraZenecaInscription sur invitationCancer du poumon non à petites cellules (NSCLC)États-Unis